Abstract: An injection-locked phase-locked loop (ILPLL) circuit includes a delay-locked loop (DLL) and an ILPLL. The DLL is configured to generate a DLL clock by performing a delay-locked operation on a reference clock. The ILPLL includes a voltage-controlled oscillator (VCO), and is configured to generate an output clock by performing an injection synchronous phase-locked operation on the reference clock. The DLL clock is injected into the VCO as an injection clock of the VCO.

Abstract: Disclosed herein are R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial. Because the R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt is more soluble and less toxic and has less side effects as an antimicrobial agent than hydrochloride and the other salts (D-aspartate and phosphate) conventionally used, the salt may be useful for oral and injectable administration.

Abstract: The present invention relates to an extract of a processed herbal medicinal plant and a composition for skin external application which contains the extract. More specifically, the composition for skin external application contains an extract of processed herbal medicinal plant, prepared through a method comprising the steps of: (a) processing an herbal medicinal plant by a process of boiling, steaming, roasting, baking or heating the medicinal plant or a combination of two or more of these processes; (b) obtaining an extract of the processed medicinal plant. The composition shows an improved antioxidant effect.

Abstract: A leucine zipper variant, a polynucleotide encoding the leucine zipper variant, a method of preparing a leucine zipper variant, a method of inhibiting HDM2- and/or HDMX using the leucine zipper variant, and a method of the prevention and/or treatment of cancer using the leucine zipper variant.

Abstract: A heteroarylamine compound includes protein kinase inhibition activity, a pharmaceutically acceptable salt thereof and a pharmaceutical composition for preventing and treating a disease caused by abnormal cell growth, which contains the compound as an active ingredient.

Abstract: The present invention relates to an extract of a processed herbal medicinal plant and a composition for skin external application which contains the extract. More specifically, the composition for skin external application contains an extract of processed herbal medicinal plant, prepared through a method comprising the steps of: (a) processing an herbal medicinal plant by a process of boiling, steaming, roasting, baking or heating the medicinal plant or a combination of two or more of these processes; (b) obtaining an extract of the processed medicinal plant. The composition shows an improved antioxidant effect.

Abstract: Disclosed herein are R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial. Because the R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt is more soluble and less toxic and has less side effects as an antimicrobial agent than hydrochloride and the other salts (D-aspartate and phosphate) conventionally used, the salt may be useful for oral and injectable administration.

Abstract: A variable valve lift apparatus of an engine includes a first body rotated at within a preset angle range by rotating a high-speed cam coupled to a camshaft, a second body coupled to the first body or decoupled from the first body and rotated within a preset angle range by rotating a low-cam coupled to the camshaft when the second body is decoupled from the first body, a latching pin provided retractably forward of the first body such that the first body is coupled to or decoupled from the second body, and an actuating unit to retractably actuate the latching pin. The degree of the lift of the valve is variably controlled in two stages of high-speed and low-speed modes through the rotary motion of the high speed cam or low speed cam by coupling or decoupling the first and second bodies to or from each other.

Abstract: A fusion protein including granzyme B, a cell penetrating peptide, a cleavage site, and a targeting moiety, a composition for cell membrane penetration comprising the fusion protein, and an anticancer composition comprising the fusion protein.

Abstract: Disclosed herein are R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial. Because the R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt is more soluble and less toxic and has less side effects as an antimicrobial agent than hydrochloride and the other salts (D-aspartate and phosphate) conventionally used, the salt may be useful for oral and injectable administration.

Abstract: The present inventive concept relates to an electrowetting display device including a lyophobic colloid material and a polymer resin such as an organic layer or a polyimide (PI), and a lyophobic layer including a supporting layer supporting the lyophobic colloid material and using a photoreactive fluorine-based surfactant for a fluorine-based material to be positioned above and for a hardened photoreactive material layer to be positioned below through exposure in a single step without separately performing a hydrophilic treatment and then a water-repellent treatment, thereby reducing the number of processes, the manufacturing time, and the cost.

Abstract: An injection-locked phase-locked loop (ILPLL) circuit includes a delay-locked loop (DLL) and an ILPLL. The DLL is configured to generate a DLL clock by performing a delay-locked operation on a reference clock. The ILPLL includes a voltage-controlled oscillator (VCO), and is configured to generate an output clock by performing an injection synchronous phase-locked operation on the reference clock. The DLL clock is injected into the VCO as an injection clock of the VCO.

Abstract: A cell having a surface coated with Annexin A1 (ANXA1), a method of detecting a substance binding to ANXA1 using the cell, and a method of preparing the cell are provided.

Abstract: Disclosed is a composition comprising an extract of at least one selected from a group consisting of Rehmannia glutinosa, licorice, Coicis Semen, Hordei Fructus, Chaenomelis Fructus, Acanthopanacis Cortex and Puerariae Radix as an active ingredient. The composition promotes adipocyte differentiation and lipid droplet formation and is effective in improving skin wrinkles, enhancing skin elasticity and preventing skin aging.

Abstract: Disclosed herein are R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial. Because the R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt is more soluble and less toxic and has less side effects as an antimicrobial agent than hydrochloride and the other salts (D-aspartate and phosphate) conventionally used, the salt may be useful for oral and injectable administration.

Abstract: A leucine zipper variant, a polynucleotide encoding the leucine zipper variant, a method of preparing a leucine zipper variant, a method of inhibiting HDM2- and/or HDMX using the leucine zipper variant, and a method of the prevention and/or treatment of cancer using the leucine zipper variant.

Abstract: The present inventive concept relates to an electrowetting display device including a lyophobic colloid material and a polymer resin such as an organic layer or a polyimide (PI), and a lyophobic layer including a supporting layer supporting the lyophobic colloid material and using a photoreactive fluorine-based surfactant for a fluorine-based material to be positioned above and for a hardened photoreactive material layer to be positioned below through exposure in a single step without separately performing a hydrophilic treatment and then a water-repellent treatment, thereby reducing the number of processes, the manufacturing time, and the cost.

Abstract: Disclosed herein are R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial. Because the R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt is more soluble and less toxic and has less side effects as an antimicrobial agent than hydrochloride and the other salts (D-aspartate and phosphate) conventionally used, the salt may be useful for oral and injectable administration.

Abstract: Disclosed are an extractor having a “pottery with dark brown glaze” called “Onggi” in Korean, and a method of extracting using the same. The extractor includes a body, a body cover, a heating part, a pottery and a gas valve. The pottery is located within the body. The extractor extracts by injecting nitrogen gas, etc. into the body through a gas valve, thereby rendering the inside of the body to be high pressure state during extraction. Thus, the inside of the body is maintained under high pressure during extraction. Accordingly, an extract is located only within the pottery, and thus changes that can be caused while an extract contacts with the body can be prevented.

Abstract: The present invention relates to a composition for skin external application containing a pine root extract. More specifically, the composition for skin external application according to the present invention contains, as an active ingredient, a pine root extract which shows various effects, including eliminating free radicals, protecting the cell membrane from damage by UV radiation, inhibiting the production of reactive oxygen species caused by UV radiation, inhibiting the reduction in the expression of superoxide dismutase (SOD) and catalase caused by UV radiation, stimulating the production of HSP70 to protect cells, inhibiting MMP-2 biosynthesis caused by UV radiation, inducing the expression of SIRT1 gene that restores DNA damage, and inducing the expression of LMNA1 gene that maintains the structure of the nuclear membrane. Ultimately, the composition of the present invention prevents skin aging.